Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Pharmaceutical efficacy of novel human-origin Faecalibacterium prausnitzii strains on high-fat-diet-induced obesity and associated metabolic disorders in mice
Ist Teil von
Frontiers in endocrinology (Lausanne), 2023-08, Vol.14, p.1220044-1220044
Ort / Verlag
Frontiers Media S.A
Erscheinungsjahr
2023
Link zum Volltext
Quelle
EZB Electronic Journals Library
Beschreibungen/Notizen
Introduction
Obesity and related metabolic issues are a growing global health concern. Recently, the discovery of new probiotics with anti-obesity properties has gained interest.
Methods
In this study, four
Faecalibacte-rium prausnitzii
strains were isolated from healthy human feces and evaluated on a high-fat diet-induced mouse model for 12 weeks.
Results
The
F. prausnitzii
strains reduced body weight gain, liver and fat weights, and calorie intake while improving lipid and glucose metabolism in the liver and adipose tissue, as evidenced by regulating lipid metabolism-associated gene expression, including ACC1, FAS, SREBP1c, leptin, and adiponectin. Moreover, the
F. prausnitzii
strains inhibited low-grade inflammation, restored gut integrity, and ameliorated hepatic function and insulin resistance. Interestingly, the
F. prausnitzii
strains modulated gut and neural hormone secretion and reduced appetite by affecting the gut-brain axis. Supplementation with
F. prausnitzii
strains noticeably changed the gut microbiota composition.
Discussion
In summary, the novel isolated
F. prausnitzii
strains have therapeutic effects on obesity and associated metabolic disorders through modulation of the gut-brain axis. Additionally, the effectiveness of different strains might not be achieved through identical mechanisms. Therefore, the present findings provide a reliable clue for developing novel therapeutic probiotics against obesity and associated metabolic disorders.